BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

There were more than 48,000 organ transplants in the United States last year. They’re commonplace now, but the practice was considered experimental only a half-century ago.

Scientists have decoded the atomic structure of Photosystem I from a 3-billion-year-old cyanobacteria lineage, offering a unique look at early oxygen-producing photosynthesis. The ancient nanodevice, ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

The "lobotomobile" crisscrossed America in the 1960s teaching about lobotomies. This dark period in psychiatric history holds ...

Three Abstracts Accepted for Oral Presentations at 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome ...

IntroductionThe global mesenchymal stem cells market is witnessing a significant transformation as advancements in ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

As the Trump administration continues to make significant cuts to NIH budgets and personnel and to freeze billions of dollars ...

Successfully separating conjoined twins was once considered impossible, but technological breakthroughs are making the ...

Organogenesis Holdings Inc.’s ORGO share price has dipped by 21.72%, which has investors questioning if this is right time to ...

The scope of the presented studies is somewhat limited, as they primarily focus on evaluating the phenotypic changes in cardiac innervation following the loss of various Slit or Robo genes.